Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis

British Journal of Rheumatology

Volumn 36, Issue 1, 1997, Pages 9-15

  Ronday, H K ^a   Smits, H H ^b   Quax, P H A ^b   Van Der Pluijm, G ^a   Lowik C W G M ^a   Breedveld, F C ^a   Verheijen, J H ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Bone; Plasminogen activation; Rheumatoid arthritis

Indexed keywords

ANTIBODY; APROTININ; GLYCEROL 2 PHOSPHATE; PLASMIN; PLASMINOGEN; RECEPTOR; SURAMIN; TRANEXAMIC ACID; UROKINASE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE MATRIX; BONE MINERALIZATION; CALVARIA; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; MOUSE; NONHUMAN; OSTEOBLAST; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; SYNOVIUM;

EID: 0030791995     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.1.9     Document Type: Article

References (49)

1. Zvaifler NJ, Firestein GS. Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994;6:783-9.
2. Werb Z, Alexander CM. Proteinases and matrix degradation. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of rheumatology, 4th edn. Philadelphia: WB Saunders, 1993.
3. Vassali J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
4. Quax PHA, Van Muijen GNP, Pedersen N et al. The plasminogen activator system in extracellular matrix degradation. Fibrinolysis 1992;6(suppl. 4):41-4.
5. Werb Z, Mainardi MD, Vater CA, Harris ED. Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017-23.
6. Bachmann F. Thrombosis and haemostasis. In: Verstraete M, Lijnen HR, Arnout J, eds. International society on thrombosis and haemostasis. Leuven: University Press, 1987.
7. Vassali J-D, Baccino D, Belin D. A cellular binding site for the Mr 55.000 form of human plasminogen activator, urokinase. J Cell Biol 1985;100:86-92.
8. Pöllänen J, Hedman K, Nielsen LS, Danø K, Vaheri A. Ultrastructural localization of plasma membrane associated urokinase plasminogen activator. J Cell Biol 1988;106:87-95.
9. Clemmensen I, Donde R, Andersen RB. The primary plasmin inhibitor in rheumatoid synovial fluid. Arthritis Rheum 1977;20:1354-8.
10. Hamilton JA. Plasminogen activator activity of rheumatoid and nonrheumatoid synovial fibroblasts. J Rheumatol 1982;9:834-42.
11. Brommer EJP, Dooijewaard G, Dijkmans BAC, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Int Rheum Dis 1992;51:965-8.
12. Kummer JA, Abbink JJ, De Boer et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-93.
13. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-6.
14. Ronday HK, Smits HH, Van Muijen GNP et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996;35: 416-23.
15. Quax PHA, Pedersen N, Masucci MT et al. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991;2:793-803.
16. Roldan A, Cubellis MV, Masucci MT et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis. EMBO J 1990;9:467-74.
17. Nolli ML, Corti A, Soffientini A, Cassani G. A monoclonal antibody that recognizes the receptor binding region of human urokinase plasminogen activator. Thromb Haemostasis 1986;56:214-8.
18. Appella E, Robinson EA, Ullrich SJ et al. The receptor-binding sequence of urokinase. J Biol Chem 1987;262:4437-40.
19. Pedersen N, Masucci MT, Møller LB, Blasi F. A non-catalytic, human urokinase plasminogen activator derivative produced by mouse cells has full receptor binding activity. Fibrinolysis 1991;5:155-64.
20. Binnema DJ, Van Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986;43:569-77.
21. Chucholowski N, Schmitt M, Rettenberger P et al. Flow cytofluorometric analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent u-PA-ligand or monoclonal antibody #3936. Fibrinolysis 1992;6 (suppl. 4):95-102.
22. Sudo H, Kodama H-A, Amagai Y, Yamamoto S, Kasai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 1983;96:191-8.
23. Kurihara N, Ishizuka S, Kiyoki M et al. Effects of 1,25-dihydroxyvitamin D3 on osteoblastic MC3T3 cells. Endocrinology 1986;118:940-7.
24. Nakatani Y, Tsunoi M, Hakeda Y et al. Effects of parathyroid hormone on cAMP production and alkaline phosphatase activity on osteoblastic clone MC3T3-E1 cells. Biochem Biophys Res Commun 1984; 123:894-8.
25. 3-responsive alkaline phosphatase in osteoblast-like cells (ROS 17/2.8 MG 63, and MC 3T3) and growth of cartilage cells in culture. J Biol Chem 1989;264:11879-86.
26. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ. Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 1992;7: 683-92.
27. Franceschi RT, Iyer BS. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells. J Bone Miner Res 1992;7:235-46.
28. Whitson SW, Whitson MA, Bowers DE, Falk MC. Factors influencing synthesis and mineralization of bone matrix from fetal bovine bone cells grown in vitro. J Bone Miner Res 1992;7:727-41.
29. Rijken DC, van Hinsbergh VWM, Sens EHC. Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res 1984;33:145-53.
30. Behrendt N, Rønne E, Danø K. Binding of the urokinase-type plasminogen activator to its cell surface is inhibited by low doses of suramin. J Biol Chem 1993;268:5985-9.
31. Jones PA, DeClerck YA. Destruction of extracellular matrices containing glycoproteins, elastin and collagen by metastatic human tumor cells. Cancer Res 1980; 40:3222-7.
32. Shirasuna K, Saka M, Hayashido K et al. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res 1993;52:147-52.
33. Ang AH, Tachas G, Campbell JH, Bateman JF, Campbell GR. Collagen synthesis by cultured rabbit aortic smooth-muscle cells. Alteration with phenotype. Biochem J 1990;265:461-9.
34. Repesh LA. A new in vitro assay for quantifying tumor cell invasion. Invasion Metastasis 1989;9: 192-208.
35. 3. Endocrinology 1993;133:553-62.
36. Greenfield EM, Gornik SA, Horowitz MC, Donahue HJ, Shaw SM. Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res 1993;8:1163-71.
37. Masuyama A, Ouchi Y, Sato F et al. Characteristics of steroid hormone receptors in cultured MC3T3-E1 osteoblast cells and effect of steroid hormones on cell proliferation. Calcif Tissue Int 1992;51:376-81.
38. Amarnani S, Merriman HL, Linkhart TA, Baylink DJ, Mohan S. Autocrine regulators of MC3T3-E1 cell proliferation. J Bone Miner Res 1993;8:157-65.
39. Danø K, Behrend N, Brunner N, Ellis V, Plough M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8(Suppl. 1):189-203.
40. Blasi F, Conese M, Møller LB et al. The urokinase receptor: Structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994;8(Suppl. 1):182-8.
41. Machanda N, Schwartz BS. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytcs. J Biol Chem 1991;226:14580-4.
42. Gonzalez-Gronow M, Gawdi G, Pizzo SV. Characterization of the plasminogen receptor of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Chem 1994;269:4360-6.
43. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase-receptor. Proc Natl Acad Sci USA 1993;90:5021-5.
44. Hamilton JA, Lingelbach S, Partridge NC, Martin TJ. Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts. Endocrinology 1985;116:2186-91.
45. Thomson BM, Atkinson SJ, McGaritty AM, Hembry RM, Reynolds JJ, Meikle MC. Type I collagen degradation by mouse calvarial osteoblasts stimulated with 1,25-dihydroxyvitamin D-3: evidence for a plasminogen-plasmin-metalloproteinase activation cascade. Biochim Biophys Acta 1989;1014:125-32.
46. Leloup G, Delaisse JM, Vaes G. Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral resorption in explanted fetal metatarsal bones. J Bone Miner Res 1994;9:891-902.
47. Anderson GI, Allan EH, Zhou H, Heersche JNM, Martin TJ. Osteoclasts activated by lowered pH express urokinase receptor message and induce greater plasminogen activation. J Bone Miner Res 1995; 10(Suppl. 1):S284.
48. De Bart ACW, Quax PHA, Löwik CWGM, Verheijen JH. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator mediated extracellular matrix degradation in human osteosarcoma cell line MG 63 by interleukin-1 alpha. J Bone Miner Res 1995;10:1374-84.
49. Vassalli JD. The urokinase receptor. Fibrinolysis 1994;8(Suppl. 1):172-81.